Autopsy report · NCT02722304
Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency
Cause of deathNo reason given
Life of this trial
- Registered 7 months before it started.
- Ran for about 1 year 10 months before it stopped.
- 7 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 3
- Sponsor
- Baxalta now part of Shire
- Sponsor type
- Industry
- Conditions
- Chronic Obstructive Pulmonary Disease; Alpha1-antitrypsin Deficiency
- Interventions
- ARALAST NP 60 mg/kg; ARALAST NP 120 mg/kg; GLASSIA 60 mg/kg; GLASSIA 120 mg/kg; Human Albumin 2%
- Participants
- 7
- Sites
- 17
- Countries
- Australia, Canada, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.